Biological indicator

ABSTRACT

This invention relates to a biological indicator derived from a composition comprising: a host organism comprising a spore forming bacteria; a reporter gene for producing an indicator enzyme; a regulatory gene; and a vehicle for inserting the reporter gene and the regulatory gene in the host organism; the host organism bearing a transposable genetic element in its genome for inserting an insertion sequence in the regulatory gene; the insertion sequence comprising a transposase, a pair of terminal inverted repeat sequences, and at least one open reading frame for expressing the transposase. The vehicle may be taken up by the host organism. The insertion sequence may be inserted in the regulatory gene. The host organism may undergo sporulation to form the biological indicator. A process and an apparatus for using the biological indicator are disclosed.

TECHNICAL FIELD

This invention relates to biological indicators. These biologicalindicators may be used for determining the effectiveness ofsterilization processes.

BACKGROUND

In the health care industry as well as in many other commercial andindustrial applications, it is often necessary to monitor theeffectiveness of processes used to sterilize equipment such as medicaland non-medical devices, instruments and other articles and materials.Sterilization monitors can be included in the batch of articles to besterilized to assay the lethality of the sterilization process. They canalso be used to validate the effectiveness of sterilization equipmentand sterilization cycles used in such equipment.

SUMMARY

Classical methods of sterility assurance typically involve exposing asterilization indicator containing one or more test organisms to thesterilization process and then measuring the outgrowth of any survivingtest organisms. Sterility may be assured if there is no outgrowth of thetest organisms following exposure to the sterilization process.Bacterial spores are typically used as the test organisms. Uponcompletion of the sterilization process, the sterilization indicator isexposed to a liquid growth support medium under conditions that wouldpromote the growth of any surviving test organism cells. The growthsupport medium often contains a chemical dye which changes color inresponse to actively growing (metabolizing) cells. Because of therequirement for growth and metabolism, the processes employing thesetest organisms typically require about 24 to 72 hours of incubationbefore the effectiveness of the sterilization process can be determined.

A problem with this process relates to the fact that many users ofsterilized articles, such as health care facilities and the like, havelimited resources and may reuse the “sterilized” articles within 24 to72 hours and sometimes immediately. In such settings, the 24 to 72 hourholding period for sterility verification may be impractical, costly andinefficient.

A detection process for reading out test results more rapidly forcertain 121° C. and 132° C. gravity and prevacuum steam sterilizationcycles and ethylene oxide sterilization cycles has been proposed. Thetime necessary to observe evidence of surviving indicator cells isreported to be as little as one hour. This process involves detectingthe catalytic activity of the enzyme alpha glucosidase. This enzyme isproduced by a microorganism as a normal component of its metabolism andmay be present in the spore coat of the microorganism both before andduring sterilization. The presence of this enzyme can be detected byreading fluorescence produced by the breakdown of a non-fluorescentenzyme substrate. Breakdown of the enzyme substrate can be an earlydetection alternative to waiting for a visual pH color change toindicate a failed sterilization process. Neither growth nor metabolismis required for the fluorometric signal. This results in a reduction inthe time required to observe a failure in the sterilization process.However, the enzyme alpha glucosidase is thermophilic in origin, and maybe more resistant to heat than the microorganism from which it isderived. This can lead to nuisance failures, a circumstance in which thetest microorganism has been, in fact, killed but the indicator enzymeindicates that the test microorganism remains viable. In addition, sincethe enzyme alpha glucosidase may be present in the spore coat of thetest microorganism and its presence does not necessitate metabolism, thedetection of this enzyme may not be a direct indication of life.

There are situations where the use of enzyme alpha glucosidase may failto discriminate an unsuccessfully sterilized load. Successful steamsterilization is dependent upon achieving an effective temperature andpressure for a minimum length of time. Bacterial spores are typicallyselected as the test organism for this process because they are highlyresistant to this combination of parameters. It takes a particularlylethal combination of temperature, pressure and time to kill bacterialspores. Although the target/reporter molecule (alpha glucosidase) is acatalytic enzyme associated with a thermophilic organism, and thussomewhat resistant to heat, it is the heat of the process whichultimately destroys the function of the enzyme. That is, pressure andtime play a reduced role in the denaturation of alpha glucosidase.Therefore, under sub-lethal pressure or time conditions the indicatorenzyme may be destroyed even though the bacterial spores may not bedestroyed. This can result in a failure to detect a non-sterilized load.

The inability of existing technology to account for all the parametersrelating to cell death means that “grow out” may be required to providethe final confirmatory result. However, a major drawback with processesrequiring what is traditionally known as grow out relates to the timedelay in obtaining results for the sterilization test. Sterilizationindicators requiring grow out normally employ the use of bacterialspores which must be cultured for at least about 24 to 72 hours toassure adequate detection of any surviving spores. During this time, thearticles that went through the sterilization process and are underevaluation should not be used until the results of the spore viabilitytest have been determined. However, as indicated above, this may beimpractical for many users of articles requiring sterilization.

U.S. Pat. No. 8,372,624 discloses a process for detecting theeffectiveness of a sterilization process wherein a geneticallyengineered biological indicator is exposed to the sterilization process.The biological indicator comprises a test organism, a reporter gene forproducing an indicator enzyme, and a repressor gene that inhibitsexpression of the reporter gene until the reporter gene is exposed to aninducer (e.g., xylose). The biological indicator may be used in a devicethat includes two compartments, one compartment for containing thebiological indicator, and the other compartment for containing a growthmedium that includes the inducer and an enzyme substrate. Once thesterilization is complete, the biological indicator is combined with thegrowth medium, and any cells from the biological indicator that havesurvived the sterilization process are incubated. The living cells fromthe biological indicator are detected when the indicator enzyme actsupon the enzyme substrate to form a product that can be detected. Aproblem that often occurs with this process involves discoloration dueto degradation of the inducer. The inducer is degraded by heating or byexposure to various sterilization mediums (e.g., vaporous hydrogenperoxide, ethylene oxide, etc.), and as a result turns brown or isotherwise discolored. This browning or discoloration can interfere withdetecting changes associated with the success or failure of thesterilization, and thereby reduces the sensitivity of the test.

Thus, a problem that has been presented by the art is to provide abiological indicator that accurately detects the effectiveness of asterilization process within a relatively short period of time, and indoing so, does not rely on the use of an inducer. This inventionprovides a solution to this problem.

This invention relates to a composition that may be used to form abiological indicator. The composition comprises: a host organismcomprising a spore forming bacteria; a reporter gene for producing anindicator enzyme; a regulatory gene; and a vehicle for inserting thereporter gene and the regulatory gene in the host organism; the hostorganism bearing a transposable genetic element in its genome forinserting an insertion sequence in the regulatory gene; the insertionsequence comprising a transposase, a pair of terminal inverted repeatsequences, and at least one open reading frame for expressing thetransposase. The vehicle may comprise a plasmid or a viral vector. Thevehicle may be taken up by the host organism. The insertion sequence maybe inserted in the regulatory gene. The host organism may then undergosporulation to form the biological indicator. The biological indicatormay comprise spores derived from the foregoing composition. While notwishing to be bound by theory, it is believed that the insertionsequence modifies the regulatory gene to allow expression of thereporter gene upon being hydrated without the necessity of employing aninducer. This allows for use of the biological indicator for monitoringthe effectiveness of a sterilization without the problems associatedwith using an inducer.

In an embodiment, the reporter gene comprises bgaB, the regulatory genecomprises xylR, the insertion sequence comprises IS5376, the vehicle isa plasmid, and the host organism comprises Geobacillusstearothermophilus.

In an embodiment, the host organism comprises Geobacillusstearothermophilus, the host organism containing a plasmid construct,the plasmid constructing comprising the sequence set out in SEQ ID No.1.

This invention relates to a biological indicator, comprising: a hostorganism comprising Geobacillus stearothermophilus, the host organismcontaining a plasmid construct, the plasmid construct having thesequence set out in SEQ ID No. 1.

This invention relates to a process, comprising: exposing an article tobe sterilized and the above-indicated biological indicator to asterilization medium.

This invention relates to a process, comprising: exposing an article tobe sterilized and the above-indicated biological indicator to asterilization medium; and detecting the presence of the indicator enzymeto determine the effectiveness of the sterilization. In an embodiment,the indicator enzyme acts upon an enzyme substrate to form anenzyme-modified product. The enzyme-modified product may comprise aluminescent, fluorescent or colored material that can be detected.

This invention relates to a sterilization monitor, comprising: a firstcompartment containing the above-indicated biological indicator, thefirst compartment being adapted to permit the biological indicator to bebrought into contact with a sterilization medium during a sterilizationprocess; and a second compartment containing a recovery medium, thesecond compartment being adapted to maintain the recovery mediumseparate from the biological indicator during the sterilization process,and to permit the recovery medium to contact the biological indicatorafter the biological indicator has been exposed to the sterilizationmedium.

BRIEF DESCRIPTION OF THE DRAWINGS

In the annexed drawings, like parts and features have like references.

FIGS. 1A-1B disclose a series of sequence listings for the IS4 family ofinsertion sequences.

FIGS. 2A-2C disclose a schematic illustration and a series of sequencelistings for the IS21 family of insertion sequences.

FIG. 3 is a schematic illustration of a sterilization monitor suitablefor use with the present invention, the sterilization monitor beingshown in a pre-activated configuration.

FIG. 4 is a schematic illustration of the sterilization monitor of FIG.3 in an activated configuration.

FIG. 5 is a schematic illustration of another embodiment of asterilization monitor suitable for use with the present invention, thesterilization monitor being shown in pre-activated configuration.

FIG. 6 is a graph showing the results of sterilization tests employingthe inventive biological indicator.

FIG. 7 is a schematic illustration of a plasmid construct containing11223 base pairs (bp).

DETAILED DESCRIPTION

All ranges and ratio limits disclosed in the specification and claimsmay be combined in any manner. It is to be understood that unlessspecifically stated otherwise, references to “a,” “an,” and/or “the” mayinclude one or more than one, and that reference to an item in thesingular may also include the item in the plural.

The phrase “and/or” should be understood to mean “either or both” of theelements so conjoined, i.e., elements that are conjunctively present insome cases and disjunctively present in other cases. Other elements mayoptionally be present other than the elements specifically identified bythe “and/or” clause, whether related or unrelated to those elementsspecifically identified unless clearly indicated to the contrary. Thus,as a non-limiting example, a reference to “A and/or B,” when used inconjunction with open-ended language such as “comprising” can refer, inone embodiment, to A without B (optionally including elements other thanB); in another embodiment, to B without A (optionally including elementsother than A); in yet another embodiment, to both A and B (optionallyincluding other elements); etc.

The word “or” should be understood to have the same meaning as “and/or”as defined above. For example, when separating items in a list, “or” or“and/or” shall be interpreted as being inclusive, i.e., the inclusion ofat least one, but also including more than one, of a number or list ofelements, and, optionally, additional unlisted items. Only terms clearlyindicated to the contrary, such as “only one of” or “exactly one of,”may refer to the inclusion of exactly one element of a number or list ofelements. In general, the term “or” as used herein shall only beinterpreted as indicating exclusive alternatives (i.e. “one or the otherbut not both”) when preceded by terms of exclusivity, such as “either,”“one of,” “only one of,” or “exactly one of.”

The phrase “at least one,” in reference to a list of one or moreelements, should be understood to mean at least one element selectedfrom any one or more of the elements in the list of elements, but notnecessarily including at least one of each and every elementspecifically listed within the list of elements and not excluding anycombinations of elements in the list of elements. This definition alsoallows that elements may optionally be present other than the elementsspecifically identified within the list of elements to which the phrase“at least one” refers, whether related or unrelated to those elementsspecifically identified. Thus, as a non-limiting example, “at least oneof A and B” (or, equivalently, “at least one of A or B,” or,equivalently “at least one of A and/or B”) can refer, in one embodiment,to at least one, optionally including more than one, A, with no Bpresent (and optionally including elements other than B); in anotherembodiment, to at least one, optionally including more than one, B, withno A present (and optionally including elements other than A); in yetanother embodiment, to at least one, optionally including more than one,A, and at least one, optionally including more than one, B (andoptionally including other elements); etc.

The transitional words or phrases, such as “comprising,” “including,”“carrying,” “having,” “containing,” “involving,” “holding,” and thelike, are to be understood to be open-ended, i.e., to mean including butnot limited to.

The term “sterilization” refers to rendering a substance incapable ofreproduction, metabolism and/or growth. While this is often taken tomean total absence of living organisms, the term may be used herein torefer to a substance free from living organisms to a degree previouslyagreed to be acceptable. Unless otherwise indicated, the termsterilization is used herein to also refer to methods and proceduresless rigorous than sterilization, for example, disinfection,sanitization, and the like. The biological indicator and the processesand apparatus described herein may be used in health care fields,scientific fields, and the like. These may be used in commercial andindustrial applications where sterilization, disinfection, sanitization,decontamination, cleaning, and the like, may be desired. The commercialand industrial applications may include processes such as foodprocessing, pasteurization, soil remediation, water remediation, and thelike.

The term “insertion sequence” (also known as an IS, an insertionsequence element, an IS element, a transposable genetic element,transposon, or jumping gene) refers to a short DNA sequence that acts asa simple transposable element. Insertion sequences typically have twomajor characteristics: they are small relative to other transposableelements (generally around 700 to 2500 bp in length) and only code forproteins implicated in the transposition activity. They are differentfrom other transposons, which also carry accessory genes such asantibiotic resistance genes.

The term “base pair” or “bp” refers to building blocks of the DNA doublehelix which contribute to the helical and folded structures of both DNAand RNA. The term “kilobase” or “kb” refers to a unit of measurementequal to 1000 base pairs.

The sterilization process for which the inventive biological indicatormay be used may comprise any sterilization process. The sterilizationprocess may include sterilization processes wherein the sterilizationmedium or sterilant may comprise steam, dry heat, radiation, plasma, aswell as one or more gaseous sterilants, one or more liquid sterilants,and the like. The radiation may comprise electron beam or anyelectromagnetic spectra including ionizing radiation, pulsed white orultraviolet light, microwave, and the like. The radiation may comprisegamma or beta radiation. The gaseous sterilants may comprise ethyleneoxide, gaseous hydrogen peroxide, and the like. The liquid sterilantsmay comprise formalin (formaldehyde gas dissolved in water andoptionally containing methanol to inhibit the formation of toxicsubstances), glutaraldehyde, peracetic acid, liquid hydrogen peroxide,and the like.

The biological indicator of the present invention may be used to examinethe lethality of sterilants against any microorganism with lessresistance to the sterilization process than the host organism providedwith the inventive biological indicator. These microorganisms mayinclude bacteria such as Escherichia coli, Legionella sp., Campylobactersp., and other enteric bacteria, as well as Staphylococcus andStreptococcus species and other human pathogenic microorganisms such asCryptosporidium.

The growth of an organism may comprise the combined result of amultitude of cellular processes. In typical biological indicatorapplications this may be observed in several ways. As cells grow anddivide their individual numbers increase to a point at which the supportmedium of the cells may change from clear to opaque (turbid). Tofacilitate this observation of growth, a pH indicator dye may be used.Growth requires energy. This energy may be provided by the ability ofthe cell to metabolize nutrients contained in the support medium. Thebreakdown products of this process may cause the support medium tobecome acidic. This acidity may induce a pH indicator dye (e.g., phenolred) to change color. As a result, growth may be observed as theconversion of the support medium from a clear red to yellow color, forexample, to a turbid yellow condition. Although these processes areslow, they represent compelling evidence of life and are generallyaccepted as the benchmark by the various sterility assurance regulatorybodies.

With the present invention, a biological indicator is provided which isderived from a composition comprising: a host organism comprising aspore forming bacteria; a reporter gene capable of producing anindicator enzyme; a regulatory gene; and a vehicle for inserting thereporter gene and the regulatory gene in the host organism; the hostorganism bearing a transposable genetic element in its genome forinserting an insertion sequence in the regulatory gene; the insertionsequence comprising a transposase, a pair of terminal inverted repeatsequences, and at least one open reading frame for expressing thetransposase. The vehicle, which may comprise a plasmid or a viralvector, is taken up by the host organism. The insertion sequence isinserted in the regulatory gene. The host organism is sporulated to formthe biological indicator. Expression of the reporter gene occurs whenthe reporter gene is hydrated, which can occur when the reporter gene isexposed to a recovery medium. Advantageously, the recovery medium ischaracterized by the absence of an inducer (e.g., xylose). What may beexposed to the sterilization process are the various and vitalmechanisms the host organism uses to survive and grow and which are alsoused for the production of the indicator enzyme. These may include theDNA polymerases used for cellular growth (and replication of the plasmidor viral vector), RNA polymerases for transcription of the metabolicrequirements of the host organism (and the plasmid or viral vector bornereporter gene, e.g., bgaB) and the ribosomal polysomes required for thetranslation of cellular proteins and expression of the reporter gene. Inorder to be effective for determining the effectiveness of asterilization process, the biological indicator should be more resistantto the sterilization than the organisms that are to be destroyed by thesterilization.

The host organism may comprise any spore forming bacteria that bears atransposable genetic element in its genome that is capable of modifyingthe regulatory gene by inserting an insertion sequence in the regulatorygene. The type of host organism used may be dependent upon a variety offactors exemplified by the type of sterilization process being used. Thehost organism may comprise bacteria of the Bacillus or Clostridiagenera. These may include Geobacillus stearothermophilus, Bacillusatrophaeus, Bacillus sphaericus, Bacillus anthracis, Bacillus pumilus,Bacillus coagulans, Clostridium sporogenes, Clostridium difficile,Clostridium botulinum, Bacillus subtilis globigii, Bacillus cereus,Bacillus circulans, or a mixture of two or more thereof, and the like.Geobacillus stearothermophilus is particularly useful.

Geobacillus stearothermophilus is widely distributed in nature. Manyspecies can be isolated from soils and muds. They are also associatedwith heated materials, such as formation waters of oil fields in Russia,Kazakhstan, and China, and hot springs in Yellowstone National Park.Both G. stearothermophilus and G. kaustophilus strains have also beenisolated from mud samples taken from the Mariana Trench. One BacillusGenetic Stock Center (BGSC) strain was also isolated from rotting woodin Florida, USA.

Geobacillus stearothermophilus (NRRL B-1172) may be equivalent to theAmerican Type Culture Collection (ATCC) strain 12980 and strain 26 fromthe collection of the National Canning Association. This is athermophilic spore-forming organism with optimal growth conditionsbetween 55-65° C. This particular strain of Geobacillusstearothermophilus is a source of the restriction endonuclease BstPI.Geobacillus stearothermophilus is classified by ATCC as a BiosafetyLevel 1 organism, according to U.S. Public Health Service guidelines. Itis not known to cause disease in healthy adult humans, animals or plantsand is not harmful to the environment.

The vegetative form of Geobacillus stearothermophilus is rod-shapedcells that produce one endospore per cell. The cell length ranges from2.0-3.5 micrometers with a cell width ranging from 0.6-1.0 micrometers.Cells occur either singly or in short chains and are motile by means ofperitrichous flagella. The cell wall structure is gram-positive, but thegram stain reaction may vary between positive and negative depending onthe age of the culture.

Geobacillus stearothermophilus can utilize hydrocarbons (C₁₀, C₁₁). Itwill produce acid but no gas upon utilization of glucose, fructose,maltose, mannose and sucrose. Phenylalanine is not deaminated, tyrosineis not degraded, indole is not produced, and the Voges-Proskauerreaction is negative.

Geobacillus stearothermophilus is a thermophilic organism whosedistinctive diagnostic characteristics include its capacity to grow at65° C. and a limited tolerance to acid.

The reporter gene may comprise lacZ, bgaB, xylE, cat, gfp, or a mixtureof two or more thereof. The term “lacZ” refers to a gene coding forβ-galactosidase. The term “bgaB” refers to the gene coding forthermostable ß-galactosidase from G. stearothermophilus. The term “xylE”refers to gene coding for catechol-2,3-dioxygenase from Pseudomouasputida. The term “cat” refers to the gene coding for chloramphenicolacetyltransferase. The term “gfp” refers to the gene for codingthermostable green fluorescent protein variants.

The regulatory gene may comprise xylR, lacI, tetR, or a mixture of twoor more thereof. The term “xylR” refers to a regulator of the xyloseoperon. The term “lacI” refers to a regulator of the lac operon. Theterm “tetR” refers to a regulator of the tet operon. The thermostablecounterparts of these may be used. The regulatory gene may be taken upby the test organism with the same vehicle used to insert the reportergene in the test organism.

The insertion sequence may be derived from the host organism and addedto the regulatory gene. The insertion sequence may comprise an IS4 or anIS21 family insertion sequence. The nomenclature used in Mahillon etal., “Insertion Sequences,” Microbiology and Molecular Biology Reviews,1998, 62(3): 725, is used in this disclosure. The Mahillon et al.article is incorporated herein by reference.

The IS4 family is depicted in FIGS. 1A-B. The insertion sequences ofthis family comprise a transposase, a pair of terminal inverted repeatsequences (IRs), and a single open reading frame for expressing thetransposase. The open reading frame extends along the length of theinsertion sequence between the terminal inverted repeat sequences. FIG.1A is a dendrogram based on alignments of the putative Tpases. The term“Tpase” is an abbreviation for transposase. FIG. 1B discloses terminalIRs of selected members.

The IS4 family of insertion sequences contains 41 members, including 13isoforms. Many members, such as IS10 and IS50, are involved in compoundtransposons. Several members carry GATC methylation sites, which, forboth IS10 and IS50, may play a modulating role in transpositionactivity.

IS10 and IS50 may be the best-characterized members of the IS4 family.Both transpose by a “cut-and-paste” mechanism, as does IS231A. IS10forms part of the composite tetracycline resistance transposon Tn10.

The IS4 family of insertion sequence may comprise IS4, IS10, IS50,IS186, IS231, IS701, IS942, IS1151, IS1170, IS1452, IS5377, IS8402,ISH27-1, ISH27-2 or ISH51-3. IS5377 may be particularly useful.

The IS21 family is depicted in FIGS. 2A-2C. The insertion sequences ofthis family comprise a transposase, a pair of terminal inverted repeatsequences, and two consecutive open reading frames for expressing thetransposase. Referring to FIGS. 2A-2C, the IS21 family members haveterminal inverted repeat sequences (IRL and IRR) with two consecutivereading frames (istA and istB) positioned between the terminal invertedrepeat sequences. The terminal inverted repeat sequences IRL and IRR areshown as solid boxes in FIG. 2A. The position of the istA and istBreading frames is also shown in FIG. 2A. The horizontal lines below showthe relative positions of the multiple repeat elements whose sequencesare presented in FIG. 2C. IstA (hatched box) together with the potentialDDE motif (stippled box) and IstB (open box) are indicated in FIG. 2A.The possibility of translational coupling between the two reading framesis indicated in FIG. 2A. The dendrogram shown in FIG. 2B is derived fromthe alignment of the istA and istB gene products. Nucleotide sequencesof the multiple terminal repeats, together with their coordinates areshown in FIG. 2C. CS (complementary strand) L1, L2, and L3, and R1 andR2, indicate internal repeated sequences at the left and right ends,respectively.

There are 15 distinct members of the IS21 family together with 6iso-ISs. They carry related terminal IRs whose lengths may vary between11 bp (IS21) and 50 bp (IS5376) and generally terminate in thedinucleotide 5′-CA-3′. Several members, but not IS21 itself, carrymultiple repeated sequences at their ends which include part of theterminal IRs and which may represent Tpase binding sites. Insertion ofthese elements results in a direct target repeat of 4 bp or 5 bp, whiletwo members (IS53 and IS408) may generate 8 bp. They exhibit twoconsecutive open reading frames: a long upstream frame designated istAand a shorter downstream frame designated istB (FIG. 2A). The putativeIstA and IstB proteins carry several blocks of highly conservedresidues. Overall identities range from 10 to 59% for IstA and from 25to 67% for IstB. The istB frame may be located in a relative readingphase of −1 (e.g., IS21 and IS5376) or +1 (e.g., IS232 and IS1326)compared to istA. It can be slightly separated from istA (17 bp forIS408) or can overlap for 1 bp (IS21) or for several base pairs (IS232,IS5376, and IS1326); it is generally preceded by a potential ribosomebinding site. The arrangement of the two reading frames suggests thattranslational coupling may occur (FIG. 2A).

The IS21 family of insertion sequence may comprise IS21, IS53, IS232A,IS408, IS1162, IS1326, IS1415 or IS5376. IS5376 is a particularly usefulinsertion sequence.

IS5376 is depicted in SEQ ID No. 1 at coordinates (2060). .(4166).IS5376 may be described, using slightly different terminology, as havingthe following segments:

Coordinates in SEQ ID No. 1 1) First inverted repeat sequence (2060) . .. (2109) 2) tnpA gene (ATP binding protein) (2120) . . . (2875) 3) tnpBgene (transposase) (2872) . . . (4074) 4) RBS (ribosome binding site)(4082) . . . (4088) 5) Second inverted repeat sequence (4177) . . .(4166)The “tnpA” and “tnpB” genes code for transposases needed by the IS5376to insert into a new site. The term “ATP-binding protein” refers to asequence of protein subunits (i.e., genomic DNA base pairs) that promotethe attachment of ATP (adenosine-5′-triphosphate) to a target protein.

The vehicle for inserting the reporter gene and the regulatory gene inthe host organism may comprise one or more plasmids or one or moreviruses (or viral vectors). When added to the host organism, theinsertion sequence may be transferred from the host organism to thevehicle. In an embodiment, the insertion sequence is inserted in theregulatory gene. In an embodiment, the regulatory gene is xylR and theinsertion sequence is IS5376 which is inserted in the xylR regulatorygene. The vehicle may be referred to as a vector. The plasmids maycomprise circular double-stranded DNA that are separate from chromosomalDNA. The plasmids may be linear. The size of the plasmids may be in therange from about 2000 to about 20000 base pairs (bp), or in the rangefrom about 5000 to about 10000 bp. One or more copies (for example, from1 to about 3000 copies, or from 1 to about 60 copies, or from about 20to about 3000 copies) of the same plasmid may be taken up by a cell ofthe test organism. The plasmids may contain one or more DNA sequencesthat serve as an origin of replication (ori). The plasmids may containone or more genetic markers. The plasmids may contain a polylinker ormultiple cloning site (MCS) which may be a relatively short regioncontaining one or more restriction sites allowing the insertion of DNAfragments. The plasmids may contain one or more genes that provide aselective marker to induce the test organism to retain the plasmid. Theselective marker may comprise an antibiotic resistance gene and/or or agene with nutritional capability. The plasmids may comprise conjugativeplasmids which contain tra-genes which perform the process ofconjugation, the sexual transfer of plasmids to another bacterium.

Naturally occurring plasmids exist over a broad range of host organismsin nature. They may comprise genes, regulatory elements and/orstructural pieces of DNA. Plasmids usually provide some advantage totheir host organism (e.g. antibiotic resistance or the ability to usecertain nutritional sources of energy) and may be tolerated by theirhost organisms for as long as this advantageous relationship may exist.Genetically engineered plasmids may comprise a patchwork of genes,regulatory elements and/or structural pieces of interest. Since thereare so many naturally occurring (and previously engineered) plasmidsavailable, there is a wide choice of genes to choose from. The genesemployed may be selected based on the desired properties of the finishedplasmid construct. These properties may include the ability to transformthe full range of useful host organisms, provide some selectiveadvantage to the host organism (e.g., antibiotic resistance), produce athermostable and rapidly detectable signal on demand. This may beaccomplished by piecing together (ligation) the required attributes inthe form of DNA segments from a variety of source plasmids. For example,the fragments may comprise origins of replication for both gram positiveand gram negative organisms, a cat gene for chloramphenicol resistance,a bgaB gene for thermostable β-galactosidase, and an xylR regulator toregulate the bgaB gene product until needed.

A plasmid of specific design may be constructed by assembling thedesired genetic elements. The genetic elements may be assembled byrestriction digest of the desired genetic sequence from a donor plasmidor organism to produce ends of the DNA which may then be readily ligatedto another genetic sequence. Typically, a 5′ or 3′ overhang may beproduced via restriction digest on both sequences targeted for ligation.Following digestion, the target sequences may be purified and thenligated together with an enzyme (ligase). The plasmid may be constructedby assembling a base plasmid containing origins of replication for bothgram positive and gram negative organisms as well as a cat gene forchloramphenicol resistance. The regulator gene (e.g., xylR) may beattached to the base plasmid by restriction digest of the base plasmidand ligation of the regulator gene segment. Following confirmation ofthe proper attachment of the regulator segment to the base segment, theprocess may be repeated for the reporter gene segment (e.g., bgaB). Uponcomplete assembly of the genetic elements and confirmation of properassembly and orientation, the plasmid may be inserted into a hostorganism. The insertion sequence may be transferred from the hostorganism and inserted in the plasmid construct at any desired locationfor which there is a complementary insertion site (e.g., the xylR).

The resulting plasmid may comprise a plasmid construct comprising areporter gene, regulatory gene and insertion sequence. The plasmidconstruct may further comprise at least one origin of replication, atleast one selectable marker, at least one inducible promoter. Theselectable marker may comprise an antibiotic resistance gene and/or agene with exogenous nutritional capability. These may includechloramphenicol, ampicillin or spectinomycin antibiotic genes, and/orxylose or lactose nutritional genes. The inducible promoter may comprisePxyIA. The term PxyIA refers to a transcription promoter that requiresxylose to remain active. The reporter gene may comprise lacZ, bgaB,xylE, cat, gfp, and the like. The plasmid may comprise two origins ofreplication. One of the origins of replication may comprise a gramnegative origin of replication and the other origin of replication maycomprise a gram positive origin of replication. The gram negative originof replication may comprise Escherichia coli. The gram positive originof replication may comprise Geobacillus stearothermophilis or Bacillusatrophaeus. The plasmid constructs that may be useful may contain fromabout 2000 bp to about 20000 bp, or from about 5000 bp to about 15000bp, or from about 10,000 bp to about 12,000 bp.

The plasmid construct that may be used is illustrated in FIG. 7 and setout in SEQ ID No. 1. This plasmid construct contains 11223 pb. Thisplasmid construct contains the following segments, which are set out inSEQ ID No. 1 at the indicated coordinates:

Coordinates xyIR′ - regulatory gene  (1746 . . . (2059) IS5376 -insertaiton sequence (2060) . . . (4166) ′xyIR - regulatory gene (4167). . . (5023) mob - mobility factor gene (6769) . . . (8016) rep - genefor replication (8245) . . . (9249) cat - chloroamphenicol acetyltransferase  (9356) . . . (10006) bgaB - reporter gene for producingbeta- (1 . . . 1196, galactosidase 10401 . . . 11223)

A complete virus particle, which may be referred to as a virion or aviral vector, may be a gene transporter that comprises nucleic acidsurrounded by a protective coat of protein, which may be referred to asa capsid. A capsid may comprise proteins encoded by the viral genome andits shape may serve as a basis for morphological distinction. Virallycoded protein units, which may be referred to as promoters, mayself-assemble to form the capsid, requiring no input from the virusgenome; however, a few viruses may code for proteins which can assistthe construction of their capsid. Proteins associated with nucleic acidmay be more technically known as nucleoproteins, and the association ofviral capsid proteins with viral nucleic acid may be referred to as anucleocapsid. The viruses may not be considered to be living organismsand may lack the means for self-reproduction outside a host cell. Theviruses used herein with bacteria may be referred to as bacteriophagesor phages. Examples of the viruses that may be used may include lambdaand M13 bacteriophages. The reporter gene, regulatory gene and insertionsequence may be inserted in the virus by first cleaving thenon-recombinant phage DNA with an endonuclease and then ligating a pieceof DNA to the two newly formed ends.

The vehicle (e.g., plasmid or viral vector) is taken up by the hostorganism by transformation or conjugation, for example, with plasmids,or transduction or transfection, for example, with viral vectors.Whether using a plasmid or a viral vector as the vehicle for thetransformation of the host, the resulting transforming DNA and the genesit contains may remain separate from the host organisms' DNA or maybecome integrated into the genome of the host organism. The insertionsequence may be inserted in the regulatory gene.

The host organism containing the vehicle may be sporulated to form thebiological indicator. Spores are a highly resistant, dormant cell typeformed from the spore forming of bacteria. Endospores (or simply spores)form within the vegetative mother cell in response to adverse changes inthe environment, most commonly nutrient depletion. The mother cellundergoes an asymmetrical cell division, where it replicates its geneticmaterial, which is then surrounded by multiple concentric and sporespecific layers. The mother cell then disintegrates, releasing themature dormant spore which requires neither nutrients, water nor air forsurvival and is protected against a variety of trauma, includingextremes of temperature, radiation, and chemical assault. These sporesare useful as biological indicators for monitoring the effectiveness ofsterilization processes.

The indicator enzymes, which may be produced by the reporter gene, maycomprise beta-D-galactosidase, beta-D-glucosidase, alpha-D-glucosidase,alkaline phosphatase, acid phosphatase, butyrate esterase, caprylateesterase lipase, myristate lipase, leucine aminopeptidase, valineaminopeptidase, chymotrypsin, phosphohydrolase, alpha-D-galactosidase,alpha-L-arabinofuranosidase, N-acetyl-beta-glucosaminidase,beta-D-cellobiosidase, alanine aminopeptidase, proline aminopeptidase,tyrosine aminopeptidase, phenylalanine aminopeptidase,beta-D-glucuronidase, fatty acid esterase, or a mixture of two or morethereof. Thermostable counterparts of these may be used.

The enzyme substrate may comprise a substance or mixture of substanceswhich when acted upon by the indicator enzyme is converted into anenzyme-modified product. In general, the enzyme-modified product maycomprise a luminescent, fluorescent, or colored material. Alternatively,the enzyme substrate may comprise one or more compounds which when actedupon by the enzyme, may yield a product which reacts with an additionalcompound or composition to yield a luminescent, fluorescent, or coloredmaterial.

There are two basic types of enzyme substrates that may be used for thedetection of specific indicator enzymes. The first type of enzymesubstrate may be either fluorogenic or chromogenic, and may be given achemical formula such as, AB. When acted upon by the indicator enzyme,AB, may break down to A+B. B, for example, may be either fluorescent orcolored. In one embodiment, two B compounds may react together toproduce the fluorescent or colored signal. A specific example of afluorogenic substrate of this type may be 4-methylumbelliferylphosphate. In the presence of the indicator enzyme phosphatase, thesubstrate may be broken down into 4-methylumbelliferone and phosphate.Other fluorogenic substrates of this type may include the derivatives of4-methylumbelliferyl, 7-amido-4-methylcoumarin, indoxyl and fluorescein.An example of a chromogenic substrate of this type may be5-bromo-4-chloro-3-indolyl phosphate. In the presence of phosphatase,the substrate may be broken down into indigo blue and phosphate. Otherchromogenic substrates of this type may include derivatives of5-bromo-4-chloro-3-indolyl, nitrophenol and phenolphthalein.

The second type of enzyme substrate may be given by the chemical formulaCD, for example, which may be converted by a specific enzyme to C+D.However, neither C nor D may be fluorescent or colored, but D may becapable of being further reacted with compound Z to give a fluorescentor colored compound, thus indicating enzyme activity. A specificfluorogenic example of this type may be the amino acid lysine. In thepresence of the enzyme lysine decarboxylase, lysine may lose a moleculeof CO₂. The remaining part of the lysine may then be called cadaverine,which is strongly basic. A basic indicator such as 4-methylumbelliferonemay be incorporated and may be fluoresce in the presence of a strongbase. A chromogenic substrate of this type may be 2-naphthyl phosphate.The indicator enzyme phosphatase, may react with the enzyme substrate toyield beta-naphthol. The liberated beta-naphthol may react with achromogenic reagent containing 1-diazo-4-benzoylamino-2,5-diethoxybenzene to produce a violet color.

The enzyme substrate may comprise a fluorogenic compound, defined hereinas a compound capable of being enzymatically modified, e.g., byhydrolysis, to provide a derivative fluorophore which has an appreciablymodified or increased fluorescence.

The fluorogenic compounds may in themselves be either non-fluorescent ormeta-fluorescent (i.e., fluorescent in a distinctly different way, e.g.,either by color or intensity, than the corresponding enzyme-modifiedproducts) and appropriate wavelengths of excitation and detection, maybe used to separate the fluorescence signal developed by the enzymemodification from any other fluorescence that may be present.

A number of enzyme substrates for indicator enzymes of diverse originsmay be used. These may include fluorogenic 4-methylumbelliferylderivatives (hydrolyzable to 4-methylumbelliferone); derivatives of7-amido-4-methylcoumarin; diacetylfluorescein derivatives; andfluorescamine.

Derivatives of 4-methylumbelliferyl that may be used as the enzymesubstrate may include:4-methylumbelliferyl-2-acetamido-4,6-O-benzylidene-2-deoxy-beta-D-lucopyranoside;4-methylumbelliferyl acetate;4-methylumbelliferyl-N-acetyl-beta-D-galactosaminide;4-methylumbelliferyl-N-acetyl-alpha-D-glucosaminide;4-methylumbelliferyl-N-acetyl-beta-D-glucosaminide;2′-(4-methylumbelliferyl)-alpha-D-N-acetyl neuraminic acid;4-methylumbelliferyl-alpha-L-arabinofuranoside; 4-methylumbelliferylalpha-L-arabinoside; 4-methylumbelliferyl butyrate;4-methylumbelliferyl-beta-D-cellobioside; methylumbelliferyl-beta-D-N,N′-diacetyl chitobioside; 4-methylumbelliferyl elaidate;4-methylumbelliferyl-beta-D-fucoside;4-methylumbelliferyl-alpha-L-fucoside;4-methylumbelliferyl-beta-L-fucoside;4-methylumbelliferyl-alpha-D-galactoside;4-methylumbelliferyl-beta-D-galactoside; 4-trifluoromethylumbelliferylbeta-D-galactoside;6,8-difluoro-4-methylumbelliferyl-beta-D-galactoside;4-methylumbelliferyl-alpha-D-glucoside;4-methylumbelliferyl-beta-D-glucoside;4-methylumbelliferyl-7,6-sulfo-2-acetamido-2-deoxy-beta-D-glucoside;4-methylumbelliferyl-beta-D-glucuronide;6,8-difluor-4-methylumbelliferyl-beta-D-glucuronide;4-methylumbelliferyl p-guanidinobenzoate; 4-methylumbelliferylheptanoate; 4-methylumbelliferyl-alpha-D-mannopyranoside;4-methylumbelliferyl-beta-D-mannopyranoside; 4-methylumbelliferyloleate; 4-trifluoromethylumbelliferyl oleate; 4-methylumbelliferylpalmitate; 4-methylumbelliferyl phosphate; 4-methylumbelliferylpropionate; 4-methylumbelliferyl stearate; 4-methylumbelliferyl sulfate;4-methylumbelliferyl-beta-D-N, N′, N″-triacetylchitotriose;4′-methylumbelliferyl 2,3,5-tri-beta-benzoyl-alpha-L-arabinofuranoside;4-methylumbelliferyl-beta-trimethylammonium cinnamate chloride;4-methylumbelliferyl 4-guanidinobenzoate; and4-methylumbelliferyl-beta-D-xyloside.

Derivatives of 7-amido-4-methylcoumarin that may be used as the enzymesubstrate may include: L-alanine-7-amido-4-methylcoumarin;L-proline-7-amido-4-methylcoumarin; L-tyrosine-7-amido-4-methylcoumarin;L-arginine-7-amido-4-methylcoumarin;L-citrulline-7-amido-4-methylcoumarin;L-leucine-7-amido-4-methylcoumarin;L-methionine-7-amido-4methylcoumarin; L-pyroglutamic acid 7-amido-4-methylcoumarin; L-aspartic acid beta-(7-amido-4-methylcoumarin);L-glutamic acid 1-(7-am ido-4-methylcoumarin); L-phenylalanine-7-amido-4-methylcoumarin; and7-glutaryl-phenylalanine-7-amido-4-methylcoumarin.

Peptide derivatives of 7-amido-4-methyl coumarin that may be used as theenzyme substrate may include: N-t-BOC-Ile-Glu-Gly-Arg 7-amido-4-methylcoumarin; N-t-BOC-Leu-Ser-Thr-Arg 7-amido-4-methylcoumarin;N-CBZ-Phe-Arg 7-am ido-4-methylcoumarin; N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin; Gly-Pro 7-amido-4-methylcoumarin; Pro-Phe-Arg7-amido-4-methylcoumarin; N-t-BOC-Val-Pro-Arg 7-amido-4-methylcoumarin;and N-glutaryl-Gly-Arg 7-amido-4-methylcoumarin.

Derivatives of diacetylfluorescein that may be used as the enzymesubstrate may include fluorescein diacetate, fluorescein dibutyrate,2′,7′-dichlorofluorescein diacetate, fluoresceindi-(beta-D-N-acetygalactosamine), fluorescein di-(beta-D-galactoside),fluorescein mono-(beta-D-galactoside), and fluorescein dilaurate.

Where the indicator enzyme whose activity is to be detected isalpha-D-glucosidase, chymotrypsin or fatty acid esterase, a fluorogenicenzyme substrate that may be used may be4-methylumbelliferyl-alpha-D-glucoside, 7-glutarylphenylalanine-7-amido-4-methyl coumarin, or 4-methylumbelliferyl heptanoate, respectively.Where the indicator enzyme whose activity is to be detected isalpha-L-arabinofuranosidase, a fluorogenic enzyme substrate that may beused may be 4-methylumbelliferyl-alpha-L-arabinofuranoside. Where theindicator enzyme whose activity is to be detected is beta-D-glucosidase,a fluorogenic enzyme substrate that may be used may be4-methylumbelliferyl-beta-D-glucoside.

An enzyme substrate that may be used may be a chromogenic compoundcapable of being enzymatically modified to give a derivativechromophore, or a product which reacts with another compound to give aderivative chromophore, which chromophore has a different or moreintense color. The chromogenic compounds may be non-colored or coloredin a distinctly different way, e.g., either by color or intensity, thanthe corresponding enzyme-modified products. Appropriate wavelengths ofexcitation and detection, in manners well known to users of colorometricinstrumentation, may be used to separate the colored signal developed bythe enzyme modification from any other color that may be present.

Chromogenic compounds that may be used as enzyme substrates may include5-bromo-4-chloro-3-indolyl derivatives; nitrophenyl derivatives; indoxylderivatives; and phenolphthalein derivatives.

Derivatives of 5-bromo-4-chloro-3-indolyl that may be used may include5-bromo-6-chloro-3-indolyl acetate, 5-bromo-4-chloro-3-indolyl acetate,5-bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside,5-bromo-4-chloro-3-indolyl-1,3-diacetate,5-bromo-4-chloro-3-indolyl-beta-D-fucopyranoside,5-bromo-4-chloro-3-indolyl-beta-D-glucopyranoside,5-bromo-4-chloro-3-indolyl-beta-D-glucuronic acid,5-bromo-4-chloro-3-indolyl phosphate, and 5-bromo-4-chloro-3-indolylsulfate.

Derivatives of nitrophenyl that may be used may include p-nitrophenoland o-nitrophenol derivatives. These include diethyl-p-nitrophenylphosphate; di-p-nitrophenyl phosphate;p-nitrophenyl-2-acetamido-2-deoxy-3-O-beta-galactopyranosyl-beta-glucopyranoside;p-nitrophenyl-2-acetamido-2-deoxy-beta-glucopyranoside; p-nitrophenylacetate; p-nitrophenyl-N-acetyl-beta-D-glucosaminide;p-nitrophenyl-beta-D-N, N′-diacetylchitobioside;p-nitrophenyl-alpha-glucopyranoside; p-nitrophenyl-alpha-maltoside;p-nitrophenyl-beta-maltoside; p-nitrophenyl-alpha-mannopyranoside;p-nitrophenyl-beta-mannopyranoside; p-nitrophenyl myristate;p-nitrophenyl palmitate; p-nitrophenyl phosphate;bis(p-nitrophenyl)phosphate; tris(p-nitrophenyl)phosphate;p-nitrophenyl-beta-glucopyranoside; p-nitrophenyl-beta-glucuronide;alpha-p-nitrophenylglycerine; p-nitrophenyl-alpha-rhamnopyranoside;p-nitrophenyl stearate; p-nitrophenyl sulfate;p-nitrophenyl-2,3,4,6-tetra-O-acetyl-beta-glucosaminide; p-nitrophenylthymidine mono-phosphate;p-nitrophenyl-2,3,4-tri-O-acetyl-beta-glucuronic acid methyl ester; andp-nitrophenyl valerate.

Useful o-nitrophenols may include o-nitrophenyl acetate,o-nitrophenyl-beta-glucoside and o-nitrophenyl-beta-D-glucopyranoside.Other useful nitrophenyl derivatives may includenitrophenyl-beta-fucopyranoside; nitrophenyl-alpha-galactopyranoside;nitrophenyl-beta-galactopyranoside; nitrophenyl butyrate; nitrophenylcaprate; nitrophenyl caproate; nitrophenyl caprylate; nitrophenyllaurate; and nitrophenyl propionate.

Indoxyl derivatives that may be used may include indoxyl-acetate;indoxyl beta-D-glucoside; 3-indoxyl sulfate; and 3-indoxyl phosphate.

Phenolphthalein derivatives that may be used may include:phenolphthalein dibutyrate; phenolphthalein diphosphate; phenolphthaleindisulfate; phenolphthalein glucuronic acid; phenolphthaleinmono-beta-glucosiduronic acid; phenolphthalein mono-beta-glucuronicacid; and phenolphthalein mono-phosphate.

The above-described chromogenic enzyme substrates may react directlywith an appropriate indicator enzyme to produce a chromophore.

Additional enzyme substrates containing 1-naphthyl, 2-naphthyl andNapthyl-AS-BI derivatives may be employed if the derivative enzymemodified product is further reacted with a chromogenic reagent, such asdiazotized dyes, e.g., 1-diazo-4-benzoylamino-2, 5-diethoxybenzene,1-diazo-4-benzoylamino-2, 5-diethoxybenzene,p-diazo-2,5-diethoxy-N-benzoyalanine, 4-chloro-2-methylbenzene diazoniumchloride, and o-aminoazotoluene diazonium salt, to produce achromophore.

Derivatives of 1-napthyl that may be used may include1-naphthyl-N-acetyl-beta-D-glucosaminide.

Derivatives of 2-naphthyl that may be used may include2-naphthyl-phosphate; 2-naphthyl-butyrate; 2-naphthyl-caprylate;2-naphthyl-myristate; L-leucyl-2-naphthylamide; L-valyl-2-naphthylamide;L-cystyl-2-naphthylamide; N-benzoyl-DL-arginine-2-naphthylamide;N-glutaryl-phenylalanine 2-naphthyl-amine; 2-naphthyl-phosphate;6-Br-2-naphthyl-alpha-D-galacto-pyranoside;2-naphthyl-beta-D-galacto-pyranoside; 2-naphthyl-2-D-glucopyranoside;6-bromo-2-naphthol-beta-D-glucopyranoside;6-bromo-2-naphthyl-2-D-mannopyranoside; and2-naphthyl-alpha-L-fucopyranoside.

Derivatives of naphthyl-AS-BI that may be used may includenaphthyl-AS-BI-phosphate; and naphthyl-AS-BI-beta-D-glucuronide.

Where the indicator enzyme whose activity is to be detected isalpha-D-glucosidase, the enzyme substrate may bep-nitrophenyl-alpha-glucopyranoside. Where the indicator enzyme whoseactivity is to be detected is alpha-L-arabinofuranosidase, the enzymesubstrate that may be used may bep-nitrophenyl-alpha-L-arabinofuranoside. Where the indicator enzymewhose activity is to be detected is ß-galactosidase, the enzymesubstrate may be 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside or4-methylumbelliferone-ß-D-galactopyranoside.

The enzyme substrate that may be used may depend upon the identity ofthe indicator enzyme whose activity is under study. Below is a list of anumber of enzyme substrates, and corresponding indicator enzymes whichmay react with the enzyme substrate to produce a product havingappreciably modified or increased fluorescence or color.

Enzyme Substrate Indicator Enzyme 4-Methylumbelliferyl acetate Esterase4-Methylumbelliferyl butyrate Esterase 4-Methylumbelliferyl elaidateLipase 4-Methylumbelliferyl-β-D-galactopyranoside β-D-Galactosidase4-Methylumbelliferyl-α-D-galactopyranoside α-D-Galactosidase4-Methylumbelliferyl-α-D-glucopyranoside α-D-Glucosidase4-Methylumbelliferyl-β-D-glucopyranoside β-D-Glucosidase4-Methylumbelliferyl heptanoate Esterase 4-Methylumbelliferyl oleateLipase 4-Methylumbelliferyl phosphate Acid or Alkaline Phosphatase4-Methylumbelliferyl propionate Esterase4-Methylumbelliferyl-β-D-galactoside β-D-Galactosidase4-Methylumbelliferyl-β-D-glucoside β-D-Glucosidase4-Methylumbelliferyl-α-D-glucoside α-D-Glucosidase4-Methylumbelliferyl-α-L-arabinofuranoside α-L-ArabinofuranosidaseL-Leucine-7-amido-4-methylcoumarin Leucine aminopeptidase7-glutaryl-phenylalanine-7-amido-4-methylcoumarin ChymotrypsinD-Melibiose α-D-Galactosidase p-Nitrophenyl phosphate Alkaline or Acidphosphatase p-Nitrophenyl acetate Lipaseo-Nitrophenyl-β-D-galactopyranoside β-D-Galactosidasep-Nitrophenyl-α-D-galactopyranoside α-D-Galactosidaseo-Nitrophenyl-β-D-glucopyranoside β-D-Glucosidasep-Nitrophenyl-α-D-glucopyranoside α-D-Glucosidasep-Nitrophenyl-β-D-glucuronide β-D-Glucuronidasep-Nitrophenyl-α-L-arabinofuranoside α-L-Arabinofuranosidasep-Nitrophenyl laurate Esterase p-Nitrophenyl myristate Esterasep-Nitrophenyl palmitate Esterase p-Nitrophenyl phosphate diNa saltAlkaline Phosphatase Phenolphthalein dibutyrate Esterase Phenolphthaleindiphosphate Acid or Alkaline phosphatase Phenolphthalein diphosphatepentaNa salt Acid or Alkaline phosphatasePhenolphthalein-β-D-glucuronide Na salt β-D-GlucuronidasePhenolphthalein-β-D-glucuronide β-D-Glucuronidase L-Phenylalanineethylester HCl Chymotrypsin Phenyl-β-D-galactopyranosideβ-D-Galactosidase Phenyl-β-D-glucuronide β-D-GlucuronidasePhenyl-β-D-glucopyranoside β-D-Glucosidase Phenyl-β-D-glucuronideβ-D-Glucuronidase Phenyl-α-D-glucoside α-D-Glucosidase Sodiumβ-glycerophosphate Acid or Alkaline phosphatase Sodium 1-naphthylphosphate Acid or Alkaline phosphatase Sodium 2-naphthyl phosphate Acidor Alkaline phosphatase 2-Naphthyl-butyrate Esterase β-Naphthyl acetateLipase 6-Br-2-naphthyl-β-D-glucoside β-D-GlucosidaseL-Leucyl-2-naphthylamide aminopeptidase Leucine L-Valyl-2-naphthylamideaminopeptidase Valine N-glutaryl-phenylalanine-2-naphthylamineChymotrypsin Naphthyl-AS-BI-phosphate Phosphohydralase Indoxyl acetateLipase N-Methylindoxyl acetate Lipase N-Methylindoxyl myristate Lipase5-Bromoindoxyl acetate Lipase 3-Indoxyl phosphate Acid or Alkalinephosphatase Indoxyl-β-D-glucoside β-D-Glucosidase 5-Br-4-Cl-3-Indolylacetate Lipase 5-Br-4-Cl-3-Indolyl phosphate Alkaline or Acidphosphatase 5-Br-4-Cl-3-Indolyl-β-D-glucuronic acid β-D-GlucuronidaseDiacetylfluorescein Lipase/esterase

Where the indicator enzyme is β-galactosidase, the enzyme substrate maycomprise 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal),5-Bromo-6-chloro-3-indolyl-β-galactopyranoside (Mag-gal),5-Bromo-3-indolyl-β-D-galactopyranoside (Bluo-gal),6-Bromo-2-naphthyl-β-D-galactopyranoside,6-chloro-3-indolyl-β-D-galacotpyranoside (Rose-gal),3-Indoxyl-β-D-galactopyranoside (Y-gal),5-Iodo-3-indoxyl-β-D-galactopyranoside,N-methylindoxyl-β-D-galactopyranoside,2-Nitrophenyl-β-D-galactopyranoside (ONPG),4-Nitrophenyl-β-D-galactopyranoside (PNPG), Phenyl-β-D-galactopranoside(P-gal), 2-Chloro-4-nitrophenyl-β-D-lactoside,4-methylumbelliferyl-β-D-galactopyranoside,4-trifluoromethylumbelliferyl-β-D-galactopyranoside, Fluoresceindi(β-D-galactopyranoside) (FDG), Fluorescein mono-β-D-galactopyranoside,Fluorescein di-(β-D-acetyl galactosamine),4-Methylumbelliferyl-β-D-lactopyranoside,2-Napthyl-β-D-galactopyranoside,8-Hydroxyquinoline-β-D-galactopyranoside, Resorufinβ-D-galactopyranoside, 3-Carboxyumbelliferyl-β-D-galactopyranoside,4-Chloromethyl-6,8-difluoroumbelliferyl-β-D-galactopyranoside,6,8-Difluor-4-methylumbelliferyl-β-D-galactopyranoside,6,8-Difluoro-4-heptadecylumbelliferyl-β-D-galactopyranoside,5-(Pentafluorobenzoylamino)-fluorescein-β-D-galactopyranoside,C₂-fluorescein-β-D-galactopyranoside,C₈-fluorescein-β-D-galactopyranoside,C₁₂-fluorescein-β-D-galactopyranoside,5-Chloromethylfluorescein-β-D-galactopyranoside,C₁₂-resorufin-β-D-galactopyranoside,7-Hydroxyl-9H-(1,3-dichlor-9,9-dimethylacridin-2-one) (DDAO), or amixture of two or more thereof.

After the sterilization process has been completed, the biologicalindicator may be contacted with or placed in a recovery mediumcontaining a nutrient growth media and an enzyme substrate. The recoverymedium may comprise an aqueous medium or aqueous solution that providesfor germination, metabolism and subsequent grow out of organisms asrequired. The aqueous medium or aqueous solution may be buffered. If thebiological indicator survives the sterilization, the indicator enzymeacts upon the enzyme substrate resulting in the formation of theenzyme-modified product having a detectable color or fluorescence.

The inventive biological indicator may be exposed to a sterilizationmedium during a sterilization process using any suitable procedure. Thismay be effected using a sterilization monitor containing the biologicalindicator. The sterilization process may comprise any sterilizationprocess. The biological indicator is exposed to a sterilization mediumduring the sterilization process, and then to the recovery medium todetermine whether the sterilization process was effective. Thesterilization medium may comprise a gaseous or liquid sterilant, dryheat, radiation, and the like. The biological indicator along with thearticles to be sterilized are exposed to the sterilization medium duringthe sterilization process. Upon completion of the sterilization process,the biological indicator is combined with the recovery medium. Thebiological indicator is then incubated in the presence of the recoverymedium for a desired period of time and examined to determine whetherthe sterilization process was effective. The inventive biologicalindicator may be used in a sterilizer to test and validate theperformance of the sterilizer and/or sterilization cycle to determinewhether the sterilizer or sterilization cycle is effective.

The sterilization monitor may be a self-contained sterilization monitorcomprising a container with two separate compartments. One of thecompartments may contain the biological indicator. The other compartmentmay contain the recovery medium. In use, the sterilization monitor andthe articles to be sterilized are exposed to the sterilization medium.Following sterilization, the sterilization monitor is activated so thatthe biological indicator comes into contact with the recovery mediumsufficiently to determine whether the sterilization process iseffective. The sterilization monitor may be used with any sterilizationprocess wherein the biological indicator is exposed to the sterilizationmedium, for example, sterilization processes employing gaseoussterilants.

Referring to FIGS. 3 and 4, a sterilization monitor 10 is disclosed. Thesterilization monitor 10 includes cap 20 that is mounted on container30. Container 30 includes a closed bottom end 31, an open upper end, andinterior space 34. The cap 20 has an outer wall 22, an open lower end,and a closed upper end 23. The cap 20 also includes an inner wall 24,and an inner chamber 26. The inner chamber 26 includes an opening 25adjacent to the bottom end of the wall 24. The inner chamber 26 containsa growth medium 50. The cap 20 includes a breakable barrier 40 coveringthe opening 25 and encapsulating the growth medium 50 within the chamber26. The sterilization monitor 10 is configured for the cap 20 to bemounted to the container 30 in a snap-fit relationship. In otherembodiments, not shown, the sterilization monitor 10 may be configuredfor the cap 20 to be mounted to the container 30 in a threadedrelationship in which the cap 20 is engaged with the container 30 bythreads and the system is activated by rotating the cap 20 with respectto the container 30, i.e., screwing the cap 20 further onto thecontainer 30.

The container 30 includes an annular projection 32 forming a ridge orlip adjacent or near the upper end of the container 30. The cap 20includes an annular projection 29 forming a ridge or lip adjacent thebottom of the cap 20. The cap 20 may be mounted onto the container 30 bysliding the ridge 29 of the cap over the ridge 32 of the container. Theridge 32 of the container 30 engages the ridge 29 on the cap 20 toprevent the cap 20 and container 30 from decoupling. The cap 20 andcontainer 30 may be sized such that the ridge 32 exerts a sufficientamount of pressure against the cap 20 to prevent the cap 20 from slidingdownward without applying an external downward force to the cap 20.

The container 30 includes one or more puncture members 36 which isadapted to break or puncture breakable barrier 40 when the cap 20 ismoved downward, and the barrier 40 contacts the point 38 of puncturemember 36. The puncture member 36 is shown as extending upwardly frombottom wall 37 of container 30. In another embodiment, not shown,puncture member 36 may extend upwardly from side wall 35, or from boththe side wall 35 and bottom wall 37.

To evaluate a sterilization process, a calibrated concentration of theinventive biological indicator is positioned within the interior 34 ofthe container 30. The biological indicator may be positioned directly onthe walls 35 of the container or provided on a support member (e.g.,support member 70) that is positioned within the container 30. The innerchamber 26 is filled with recovery medium 50. The sterilization monitor10 is then assembled by mounting the cap 20 on the container 30. The cap20 may be mounted by snap-fitting the cap 20 onto the container 30 asdescribed above, or, for example, by a threaded mounting. With referenceto FIG. 3, the cap 20 is mounted on the container 30 in a first,non-activated (or open) position such that the breakable barrier 40remains intact and is not punctured by the puncture member 36.

With the sterilization monitor 10 assembled such as shown in FIG. 3, thesterilization monitor 10 then can be subjected to a sterilizationprocess. The cap 20 has apertures 28 through which a sterilant vaporenters the sterilization monitor 10. The sterilant enters the capthrough the apertures 28 (into the space between the wall 22 and thewall 24) and flows into the container 30 through a space 60 definedbetween the exterior surface of the inner wall 24 of the cap 20 and theinner surface of the wall 35. The sterilant vapor flows into thecontainer 30 and contacts the biological indicator.

After the sterilization process is completed, the sterilization monitor10 may be activated by moving the cap 20 downward toward the container30 to a second (or closed or activated) position, which is illustratedin FIG. 4. The cap 20 is moved downward by applying a sufficientdownward force or pressure on the cap 20. As the cap 20 is moveddownward, the breakable barrier 40 is brought into contact with thepoint 38 of puncture member 36, and eventually moved into a positionsuch that the point 38 punctures the breakable barrier 40. When thebreakable barrier 40 is punctured, the growth medium 50 drains into theinterior space 34 of the container 30 and contacts the biologicalindicator. It may be desirable to move the cap 20 downward with atwisting motion to effect a greater or maximum opening of the breakablebarrier 40 to ensure complete drainage of the inducer fluid into thecontainer.

The inner surface of the cap 20 includes a second annular projection 27.The cap 20 may be moved downward to a position such that the upperportion of the projection 27 engages the bottom of ridge 32 of thecontainer 30 to hold the cap 20 in a second, closed/activated position.The closed/activated position holds the cap 20 in a sealed relationshipwith the container 30. The sterilization monitor 10 is then incubatedfor a sufficient period of time to allow microorganism viability to bedetermined. During incubation, any viable microorganisms from thebiological indicator will metabolize and grow. This metabolism andgrowth releases byproducts into the recovery medium 50. The byproductsmay be detected by any selected property including, for example, pHchange, color change, opacity, fluorescence, and the like.

In another embodiment, the cap 20 does not include the second projection27 to maintain the container in the closed position. The container 30may include another annular projection or a set of detents (not shown)on the outside of the container 30 and located below the ridge 32, whichprojection or detents may be adapted to engage the ridge 29 on the capto maintain the container 30 in a closed position. U.S. Pat. No.5,770,393 illustrates such a configuration, and this patent isincorporated herein by reference for its teachings relating toconfigurations of cap and container.

In another embodiment, the inner surface of the cap 20 and the outersurface of the container 30 may be threaded, and the cap 20 may be movedinto and maintained in a closed position by screwing the cap 20 onto thecontainer 30, in which the cap 20 may be threaded as shown, e.g., inU.S. Pat. No. 8,173,388 B2, which is incorporated herein by reference.

The cap 20, in the embodiment illustrated in FIGS. 3 and 4 is shown ashaving the aperture 28 to allow for the ingress of sterilant into thesterilization monitor 10. It will be appreciated, however, that the cap20 need not be provided with such a feature. The number, size, shape,and/or location of the aperture(s) may be selected as desired, withconsideration of the particular sterilant with which the sterilizationindicator is to be used. For example, the location, shape, and size ofthe apertures in the cap 20 and/or the container 30 may be selected toprovide a tortuous path for the entrance and exit of the sterilizationmedium between the biological indicator and the surroundingenvironments. In another embodiment, the space between the side wall ofthe cap 22 and the outer wall of the vial 30 may be sufficient toprovide a torturous path without having to provide an aperture in eitherthe cap or the vial. The tortuous path may also serve to inhibit orprevent contamination from external agents, and to make certain that anadequate amount of sterilant is available. By including the tortuouspath, it is more likely that the entire load will be exposed to thesterilant thereby killing any extant microorganisms before the testorganism in the sterilization monitor 10 is killed.

Apertures may be provided in the container 30 in addition to or as analternative to providing apertures in the cap 20. Additionally, ifapertures are provided in the container 30, they may be located suchthat the growth medium 50 does not leak or spill out through suchapertures when the sterilization monitor 10 is activated and the barrier40 is broken.

FIG. 5 depicts sterilization monitor 10 in which an aperture 80 isformed in the sidewall 35 of the container 30 at an appropriateposition, in addition to the apertures 28 in the cap 20. The aperture 80shown in FIG. 5 is in the sidewall 35 of the container 30 near the topof the container 30, in the vicinity of the point 38 of the puncturemember 36, to avoid leakage or spilling after activation. As can be seenfrom FIG. 5, after activation, the aperture 80 at this location will becovered by the cap 20 in the activated position. It is noted that thesterilization monitor 10 shown in FIG. 5 includes the aperture 28 in thecap 20, but this may not be necessary. In one embodiment (not shown),the container 30 includes the aperture 80 and is used with a cap similarto the cap 20, but which does not include the aperture 28. Thus, anaperture can be provided either in the cap 20 or in the container 30, orin both the cap 20 and the container 30. Alternatively, no aperture maybe required so long as a pathway is provided between the cap 20 andcontainer 30 while in the unactivated state.

After the sterilization process has been completed, the cap 20 ispressed or twisted downward such that the point 38 of the puncturemember 36 penetrates and breaks the breakable barrier 40 releasing therecovery medium 50 in the space 26 to mix with and incubate any of themicroorganisms of the biological indicator that may have survived thesterilization process.

The recovery medium may comprise an aqueous medium or aqueous solutionthat includes an enzyme substrate and provides for germination,metabolism and subsequent grow out of organisms as required. Therecovery medium may be buffered. The indicator enzyme (e.g.,beta-galactosidase), if present as a result of having been produced bythe reporter gene in any surviving biological indicator microorganisms,may act upon the enzyme substrate to form an enzyme-modified productwhich can be detected.

The recovery medium may comprise a lysogeny broth (LB). LB broth is anutritionally rich medium used for the growth of bacteria. An example ofan LB broth that may be used is as follows:

Deionized water 800 mL NaCl 10 g/l Tryptone 10 g/l Yeast extract 5 g/lDeionized water to provide final volume of 1 liter 5N NaOH to adjust pHto 7.0The pH of the recovery medium may be in the range from about 5 to about9.5, or about 6.5 to about 7.5, or about 7.0.

The concentration of enzyme substrate in the recovery medium may bedependent upon the identity of the enzyme substrate and the indicatorenzyme, the amount of enzyme-modified product that must be generated tobe detectable, either visually or by instrument, and the amount of timerequired to determine whether indictor enzyme is present. The amount ofenzyme substrate that may be sufficient may be the amount needed toreact with any indicator enzyme that may be present after thesterilization has been completed such that an enzyme-modified product ata molar concentration of at least about 10⁻¹⁵ molar may be producedwithin a period of up to about 4 hours, or a molar concentration of atleast about 10⁻⁸ molar within a period up to about 2 hours.

The recovery medium may be combined with the biological indicator afterthe biological indicator has been subjected to the sterilization cycle.The recovery medium containing the biological indicator can then beincubated. Incubation may be continued for a period of time and underconditions sufficient to liberate a detectable amount of the indicatorenzyme, assuming any of the biological indicator remains functional. Ingeneral, the amount of indicator enzyme which may be detectable may beas low as about 1×10⁻¹⁵ molar. The incubation conditions may besufficient to generate at least about 1×10⁻⁸ molar of indicator enzyme,or from about 1×10⁻⁶ to about 1×10⁻⁵ molar of indicator enzyme. Theincubation time and temperature needed to produce a detectable amount ofindicator enzyme may depend upon the identity of the indicator enzyme,and the concentration of the indicator enzyme in the growth medium. Theincubation temperature may be in the range from about 20° C. to about70° C. The incubation time may be in the range up to about 4 hours, orin the range from about 0.01 to about 4 hours, or in the range fromabout 0.01 to about 3 hours, or in the range from about 0.01 to about 2hours, or in the range from about 0.01 to about 1 hour. The indicatorenzyme acts upon the enzyme substrate to form an enzyme-modified productwhich can be detected. Detection can be achieved within a period of timeof up to about 4 hours, or about 0.01 to about 4 hours, or about 0.01 toabout 3 hours, or about 0.01 to about 2 hours, or about 0.01 to about 1hour, or about 0.01 to about 0.7 hour, or about 0.01 to about 0.5 hour.

Generally applicable methods for detecting the enzyme-modified productmay include photometric, potentiometric, gravimetric, calorimetric,conductometric, or amperometric techniques. Fluorometric orspectrophotometric methods may be used.

The biological indicator, although herein described primarily in termsof a single indicator enzyme, may provide a plurality of indicatorenzymes. For example, the biological indicator may provide three typesof indicator enzymes, one enzyme being resistant to heat, a second beingresistant to gaseous sterilizing media, and a third being resistant toradiation, e.g., gamma or beta irradiation.

This invention provides a number of advantages over the prior art. Thesemay include sourcing an enzyme (e.g., beta galactosidase) solely on thebasis of signal generation strategy. By limiting the role of theindicator enzyme to signal generation, the need to match or correlatethe susceptibility of the indicator enzyme to that of the host organismmay be eliminated.

Advantages of using the inventive biological indicator include providingresults of whether the sterilization is effective within a relativelyshort period of time in the range up to about 4 hours, or in the rangefrom about 0.01 to about 4 hours, or in the range from about 0.1 toabout 3 hours, or in the range from about 0.1 to about 2 hours, or inthe range from about 0.2 to about 1 hour. By virtue of the use of theinventive biological indicator, it may be possible to measure theviability of a host organism directly, rather than by indirectmeasurement of a surrogate molecule. The use of the biological indicatormay not be limited to any particular method of sterilization. That is,the biological indicator may be used for any sterilization process. Theeffectiveness of a sterilization process may be determined using theinventive biological indicator without requiring grow out to providefinal confirmation of the effectiveness of the sterilization. By usingthe disclosed biological indicator, it may not be necessary to employ anelectrochemical sensor to determine whether the sterilization iseffective, although more rapid results with a sensor may be possible.The biological indicator may be amendable to use with instant readapplications such as chip or sensor applications. The biologicalindicator may be used with any sterilization process employing a mostresistant organism, clinically significant organism or bio-warfareorganism.

The use of the inventive biological indicator for detecting theeffectiveness of a sterilization process may involve the use ofmeasurement based on a genetic theory model (only a living cell canexpress a gene). The biological indicator may respond to any lethalevent or combination of lethal events (transcription, translation,etc.). The biological indicator may provide a fast acting response toany biocidal mode of action (steam, peracetic acid, ethylene oxide,liquid formaldehyde, gaseous formaldehyde, stabilized liquid hydrogenperoxide, vaporous hydrogen peroxide, dry heat, ozone,ortho-phthalaldehyde, gluteraldehyde, chloramines, quaternary amines,phenolics, iodophores, ionizing radiation, ultraviolet radiation, pulsedwhite light, plasma, microwave radiation, etc.).

The plasmid construct illustrated in FIG. 7 and set out in SEQ ID No. 1comprises a base plasmid with a disrupted xylR regulatory gene segment,a bgaB reporter gene segment, and an insertion sequence. The insertionsequence is IS5376, which is inserted in the xylR regulatory genesegment. Referring to FIG. 7 and SEQ ID No. 1, mob, cat and rep are partof the original base plasmid. Mob (mobility factor gene) may enhancemobility of the plasmid between hosts via conjugation. Cat(chloroamphenicol acetyl transferase) may provide selective pressure toensure that the host cells that grow include the plasmid. Rep is a genefor replication. The plasmid construct may be constructed by ligation ofan intact xylR regulatory gene segment to the base plasmid. Followingsuccessful attachment of the xylR regulatory gene segment to the baseplasmid, the process may be repeated for the bgaB reporter gene segment.The plasmid construct may be taken up by Geobacillus stearothermophilus,which functions as a host organism. The host organism may modify thexylR regulatory gene segment by inserting the insertion sequence IS5376in the xylR regulatory gene segment. The plasmid construct may contain11223 base pairs. The host organism may then be sporulated to form abiological indicator.

Example 1

Geobacillus stearothermophilus (NRRL B-1172, also known as ATCC 12980)is the recipient organism and acts as a host for insertion of theplasmid construct illustrated in FIG. 7 and set out SEQ ID No. 1(hereinafter sometimes referred to as the SEQ ID No. 1 plasmidconstruct). The Geobacillus stearothermophilus is chemically transformedby a modification of the common processes described in Sambrook et al.(Molecular Cloning a laboratory manual-3rd edition). The resultingtransformant bears from 5 to 50 copies of the SEQ ID No. 1 plasmidconstruct, depending on culture conditions in the laboratory, and isstable indefinitely in the presence of selective pressure. Thetransformed cells are propagated in the presence of the antibioticchloramphenicol to ensure the selection of the transformed state andthen sporulated, cleaned and dispensed into a Self Contained BiologicalIndicator (SCBI). Spores prepared in this manner are stable in theabsence of a selective antibiotic during storage and through to theiruse in the SCBI. Once removed from selective pressure and allowed togerminate, the vegetative form of these cells reverts to their originalphenotypic sensitivity to chloramphenicol within four passages on platesnot containing the antibiotic. With the exception of the plasmid, thespores remain equivalent to their wild-type counterparts in all otherways including resistance to steam sterilization.

The SEQ ID No. 1 plasmid construct is made up of fragments from apre-existing plasmid and DNA from three donor cells. The plasmid vectorbackbone is originally obtained from a donor plasmid pNW63. The donorplasmid pNW63 is derived in whole from its precursor pNW33N after aduplicated fragment has been removed. The donor plasmid pNW63 is thesource for the necessary mobility (mob), replication (rep) andchloramphenicol resistance (cat) genes used in the construction of theSEQ ID No. 1 construct. The original plasmid pNW33N, is a fifthgeneration vector that stably replicates in Geobacillusstearothermophilus. The donor plasmid pNW63 is obtained from theBacillus Genetics Stock Center (BGSC) in an E. coli host strain JM109.It features a large multiple cloning site and encodes a thermostablechloramphenicol acetyltransferase variant that is expressed in bothgram-positive and gram-negative lab strains.

In addition to the plasmid DNA described above, three additional DNAelements are donated from other organisms. Terminators (T1T2) arederived from the rrnB gene of Escherichia coli K12. The reporter elementis derived from the bgaB gene and is donated by Bacillusstearothermophilus (subsequently reclassified as Geobacilluskaustophilus). The expression module xylR comes from thexylose-utilization operon of the non-pathogenic Bacillus megateriumstrain DSM319.

The remaining DNA segments making up the SEQ ID No. 1 plasmid constructare non-coding, miscellaneous structural features carried over fromprevious hosts and constructs. They are desirable in that they providestructural integrity, engineered restriction sites and help maintainappropriate open reading frames.

Once the various sources for the desired genes are located and obtained,they are studied relative to the location of useful restriction sites.These are short DNA sequences that interact with specific restrictionendonucleases that are readily available from multiple commercialsources. The selection of which restriction endonucleases to use isbased on the presence of the corresponding restriction sites flankingthe coding regions for each gene desired. Once the restrictionendonucleases are selected, they are combined with the source DNA andincubated under conditions known for each enzyme (e.g. 37° C. for 30minutes). This results in DNA fragments which can be identified by theirrelative lengths when analyzed by gel electrophoresis (all methods arecontained in Sambrook and many other commonly available lab manuals andalso in technical information from the enzyme vendors). The desiredfragments are isolated and purified by known methods.

The desired fragments are then combined in order and exposed to a DNAligase enzyme under conditions also detailed in Sambrook et al. Thisrejoins the formerly separate fragments into the sequence (e.g.incubation at 37° C. for 30 minutes or at 4° C. for an hour). Eachrestriction product has two ends on a linear fragment. It should also benoted that in the ligation step like ends bind to like ends only in thisprocess. In other words, digestion of pNW63 results in a linear fragmentwith a ‘green’ end and a ‘black’ end which when combined with thePxyIA+xylR fragments from B. megaterium (itself having a ‘brown’ end anda ‘green’ end) the two fragments are joined through their respective‘green’ ends. Thus, after combining all of the various restrictionfragments through their common ends that are fragments flanked by two‘black’ ends. The order may be green/green, brown/brown, orange/orangeleading to a long fragment with two black ends which can then be joinedby established means to join black/black and thus forming a circularconstruct. Any sequence of joining steps involving like to like mayresult in the same final product.

Example 2

A series of tests using a biological indicator (BI) in the form ofGeobacillus stearothermophilus spores that contain the plasmid constructset out in SEQ ID No. 1 is conducted. Four unsterilized BIs (positivecontrol) are run side-by-side with four BIs that are sterilized. Thesterilized BIs are processed in a AMSCO SV120 steam autoclave using astandard gravity 121° C., 30 minute cycle. The BIs are placed in arecovery medium that contains an enzyme substrate, the enzyme substratebeing 4-methylumbelliferyl-beta-D-galactopyranoside (MUG). The BIs areanalyzed in a fluorescent incubator reader with the results being shownin FIG. 6. The curve labeled A is for the BIs that are sterilized, andthe curve labeled B is for the BIs that are not sterilized. As indicatedby the positive slope in curve B, active beta-galactosidase isconstitutively and continuously produced which in the presence of theMUG produces a fluorescence. Only living spores can do this (proof oflife). The curve labeled A is from identical BI comprising the samematerials but after having been exposed to the steam sterilizationcycle. The flat line demonstrates that when the spores are killed, nobeta-galactosidase is produced, and an increasing fluorescence is notobserved over the same time interval (proof of death). The flat-linefluorescence which is seen is “native or back-ground” fluorescence seenin most materials but which does not increase over time.

While the disclosed invention has been explained in relation to specificembodiments, it is to be understood that various modifications thereofwill become apparent to those skilled in the art upon reading thespecification. Therefore, it is to be understood that the inventiondisclosed herein is intended to cover such modifications as may fallwithin the scope of the appended claims.

1. A composition, comprising: a host organism comprising a spore formingbacteria selected from the group consisting of Geobacillusstearothermophilus, Bacillus atrophaeus, Bacillus sphaericus, Bacillusanthracis, Bacillus pumilus, Bacillus coagulans, Bacillus subtilisglobigii, Bacillus cereus, or Bacillus circulans; a reporter gene forproducing an indicator enzyme; a regulatory gene; and a vehicle forinserting the reporter gene and the regulatory gene in the hostorganism; the host organism bearing a transposable genetic element inits genome for inserting an insertion sequence in the regulatory gene;the insertion sequence being selected from the group consisting ofIS8402, ISH27-1, ISH27-2 and ISH51-3; wherein the vehicle is taken up bythe host organism, the insertion sequence is inserted in the regulatorygene, and the host organism undergoes sporulation. 2-4. (canceled) 5.The composition of claim 1 wherein the host organism comprisesGeobacillus stearothermophilus.
 6. The composition of any claim 1,wherein the reporter gene comprises lacZ, bgaB, xylE, cat, gfp, or amixture of two or more thereof.
 7. The composition of any claim 1,wherein the indicator enzyme comprises beta-D-galactosidase,beta-D-glucosidase, alpha-D-glucosidase, alkaline phosphatase, acidphosphatase, butyrate esterase, caprylate esterase lipase,chloroamphenicol acetyltransferase, catechol-2,3-dioxygenase, myristatelipase, leucine aminopeptidase, valine aminopeptidase, chymotrypsin,phosphohydrolase, alpha-D-galactosidase, alpha-L-arabinofuranosidase,N-acetyl-beta-glucosaminidase, beta-D-cellobiosidase, alanineaminopeptidase, proline aminopeptidase, tyrosine aminopeptidase,phenylalanine aminopeptidase, beta-D-glucuronidase, fatty acid esterase,or a mixture of two or more thereof.
 8. The composition of claim 1,wherein the reporter gene comprises bgaB, the reporter gene producing anindicator enzyme comprising beta-galactosidase.
 9. The composition ofclaim 1, wherein the regulatory gene comprises xylR, lacI, tetR, or amixture of two or more thereof. 10-17. (canceled)
 18. The composition ofclaim 1, wherein the vehicle comprises a plasmid or a viral vector. 19.The composition of claim 18 wherein the plasmid comprises a circulardouble-stranded DNA.
 20. The composition of claim 18 wherein the plasmidis linear.
 21. The composition of claim 18 wherein the size of theplasmid is in the range from about 2000 to about 20000 base pairs. 22.The composition of claim 18 wherein from 1 to about 3000 copies of theplasmid are taken up by a cell of the test organism.
 23. The compositionof claim 18 wherein the plasmid comprises one or more origins ofreplication.
 24. The composition of claim 18 wherein the plasmidcomprises one or more genetic markers.
 25. The composition of claim 18wherein the plasmid comprises one or more multiple cloning sites. 26.The composition of claim 18 wherein the plasmid comprises one or moregenes that provide a selective marker to induce the test organism toretain the plasmid.
 27. The composition of claim 18 wherein the plasmidcomprises a gram negative origin of replication and a gram positiveorigin of replication.
 28. The composition of claim 27 wherein the gramnegative origin of replication comprises Escherichia coli, and the grampositive origin or replication comprises Geobacillus stearothermophilus,Bacillus atrophaeus, or a mixture thereof.
 29. The composition of claim18 wherein the plasmid comprises an antibiotic resistance gene and/or agene with exogenous nutritional capability.
 30. The composition of claim18 wherein the plasmid comprises a chloramphenicol, ampicillin orspectinomycin antibiotic gene, and/or a xylose, lactose or amino acidnutritional gene.
 31. The composition of claim 18 wherein the viralvector comprises at least one gene transporter that comprises nucleicacid surrounded by a capsid.
 32. The composition of claim 18 wherein theviral vector comprises at least one bacteriophage.
 33. The compositionof claim 18 wherein the viral vector comprises lambda or M13bacteriophage.
 34. The composition of claim 1 wherein the reporter genecomprises bgaB, the regulatory gene comprises xylR, the vehicle is aplasmid, and the host organism comprises Geobacillus stearothermophilus.35-65. (canceled)